Virology- and immunology-based gene therapy for cancer

Cancer Immunology, Immunotherapy

Volumn 55, Issue 11, 2006, Pages 1420-1425

  Tagawa, Masatoshi ^a,b   Kawamura, Kiyoko ^a   Shimozato, Osamu ^a   Ma, Guangyu ^a,b   Li, Quanhai ^a,b   Suzuki, Nobuo ^b   Shimada, Hideaki ^b   Ochiai, Takenori ^b  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Adenovirus; Cytokine; E1A; IL 12 family; Promoter

Indexed keywords

CD4 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; CYTOKINE; E1A PROTEIN; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 23; INTERLEUKIN 27; MIDKINE; ONCOLYTIC VIRUS; ONYX 015; PROTEIN P28; PROTEIN P35; TUMOR ANTIGEN;

ADENOVIRUS; ANTIGEN PRESENTATION; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL ACTIVATION; CELLULAR IMMUNITY; CONFERENCE PAPER; CYTOKINE PRODUCTION; DENDRITIC CELL; FEASIBILITY STUDY; HOST RESISTANCE; HUMAN; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR IMMUNITY; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRUS E1A PROTEINS; ANTIGEN PRESENTATION; ANTIGENS, CD95; CYTOKINES; DENDRITIC CELLS; FAS LIGAND PROTEIN; GENE THERAPY; HUMANS; IMMUNOLOGIC TECHNIQUES; IMMUNOTHERAPY; INTERLEUKIN-12; MEMBRANE GLYCOPROTEINS; MODELS, BIOLOGICAL; NEOPLASMS; TUMOR NECROSIS FACTORS; VIROLOGY;

EID: 33746877051     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0173-3     Document Type: Conference Paper

References (37)

1. Murphy A, Westwood JA, Teng MWL, Moeller M, Darcy PK, Kershaw MH (2005) Gene modification strategies to induce tumor immunity. Immunity 22:408
2. Relph KL, Harrington KL, Pandha H (2005) Adenoviral strategies for the gene therapy of cancer. Semin Oncol 32:573
3. Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2:293
4. Banchereau J, Steiman RM (1998) Dendritic cells and the control of immunity. Nature 392:245
5. Tada Y, O-Wang J, Takiguchi Y, Tatsumi K, Kuriyama T, Okada S, Tokuhisa T, Sakiyama S, Tagawa M (2002a) A novel role for Fas ligand in facilitating antigen acquisition by dendritic cells. J Immunol 169:2241
6. Nieuwenhuis EE, Neurath MF, Corazza N, Iijima H, Trgovcich J, Wirtz S, Glickman J, Bailey D, Yoshida M, Galle PR, Kronenberg M, Birkenbach M et al (2002) Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice. Proc Natl Acad Sci USA 99:16951
7. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, Hibbert L, Churakova T, Travis M, Vaisberg E, Blumenschein WM, Mattson JD et al (2002) IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity 16:779
8. Chen Q, Ghilardi N, Wang H, Baker T, Xie MH, Gurney A, Grewal IS, de Sauvage FJ (2002) Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature 407:916
9. Chiyo M, Shimozato O, Yu L, Kawamura K, Iizasa T, Fujisawa T, Tagawa M (2005) Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int J Cancer 115:437
10. Yoon T-KL, Shichinohe T, Laquerre S, Kasahara N (2001) Selectively replicating adenoviruses for oncolytic therapy. Curr Cancer Drug Targets 1:85
11. Kruyt FAE, Curiel DT (2002) Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther 13:485
12. Post DE, Khuri FR, Simons JW, Van Meir EG (2003) Replicating oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 14:933
13. Bell JC, Lichty B, Stojal D (2003) Getting oncolytic virus therapies off the ground. Cancer Cell 4:7
14. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373
15. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C et al (2000) A controlled trial of intratumoral ONXY-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluoroucil in patients with recurrent head and neck cancer. Nat Med 6:879
16. O'Shea CC, Saria C, Bagus B, McCormick F (2005) Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015oncolytic viral therapy. Cancer Cell 8:61
17. Mawatari F, Tsuruta S, Ido A, Ueki T, Nakao K, Kato Y, Tamaoki T, Ishii N, Nakata K (1998) Retrovirus-mediated gene therapy for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by human α-fetoprotein enhancer directly linked to its promoter. Cancer Gene Ther 5:301
18. Maeda T, O-Wang J, Matsubara H, Asano T, Ochiai T, Sakiyama S, Tagawa M (2001) A minimum c-erbB-2 promoter-mediated expression of herpes simplex virus thymidine kinase gene confers selective cytotoxicity of human breast cancer cells to ganciclovir. Cancer Gene Ther 8:890
19. Tsutsui J, Kadomatsu K, Matsubara S, Nakagawara A, Hamanoue M, Takao S, Shimizu H, Ohi Y, Muramatsu T (1993) A new family of heparin-binding growth/differentiation factors: Increased midkine expression in Wilms' tumor and other human carcinomas. Cancer Res 53:1281
20. Aridome K, Tsutsui J, Takao S, Kadomatsu K, Ozawa M, Aikou T, Muramatsu T (1995) Increased midkine gene expression in human gastrointestinal cancers. Jpn J Cancer Res 86:655
21. Takei Y, Kadomatsu K, Matsuo S, Itoh H, Nakazawa K, Kubota S, Muramatsu T (2001) Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 61:8486
22. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R (1997) An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 57:1814
23. Miyauchi M, Yoshida Y, Tada Y, Narita M, Maeda T, Bahar R, Kadomatsu K, Muramatsu T, Matsubara S, Nakagawara A, Sakiyama S, Tagawa M (2001) Expression of herpes simplex virus-thymidine kinase gene controlled by a promoter region of the midkine gene confers selective cytotoxicity to ganciclovir in human carcinoma cells. Int J Cancer 91:723
24. Yu L, Hamada K, Namba M, Kadomatsu K, Muramatsu T, Matsubara S, Tagawa M (2004) Midkine promoter-driven suicide gene expression and -mediated adenovirus replication produced cytotoxic effects to immortalized and tumour cells. Eur J Cancer 40:1787
25. + cells by a retargeted adenovirus vector. J Viol 74:2567
26. Hemminki A, Kanerva A, Liu B, Wang M, Alvarez RD, Siegal GP, Curiel DT (2003) Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res 63:847
27. Gaggar A, Shayakhmetov DM, Lieber A (2003) CD46 is a cellular receptor for group B adenoviruses. Nat Med 9:1408
28. Yu L, Takenobu H, Shimozato O, Kawamura K, Nimura Y, Seki N, Ugai K, Tanzawa H, Shimada H, Ochiai T, Tagawa M (2005) Increased infectivity of adenovirus type 5 bearing type 11 or type 35 fibers to human esophageal and oral carcinoma cells. Oncol Rep 14:831
29. Segerman A, Atkinson JP, Marttila M, Dennerquist V, Wadell G, Arnberg N (2003) Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 77:9183
30. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF (2005) Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65:3307
31. Tada Y, O-Wang J, Takiguchi Y, Tatsumi K, Kuriyama T, Tagawa M (2002b) T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells. Int J Mol Med 9:281
32. Tada Y, O-Wang J, Seimiya M, Takiguchi Y, Tatsumi K, Kuriyama T, Tagawa M (2002c) Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells. Anticancer Res 22:831
33. Tada Y, O-Wang J, Wada A, Takiguchi Y, Tatsumi K, Kuriyama T, Sakiyama S, Tagawa M (2003a) Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity. Cancer Gene Ther 10:134
34. Tada Y, O-Wang J, Yu L, Shimozato O, Wang Y-Q, Takiguchi Y, Tatsumi K, Kuriyama T, Takenaga K, Sakiyama S, Tagawa M (2003b) T-cell-dependent antitumor effects produced by CD40 ligand expressed on mouse lung carcinoma cells are linked with the maturation of dendritic cells and secretion of a variety of cytokines. Cancer Gene Ther 10:451
35. Trinchieri G, Pflanz S, Kastelein RA (2003) The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 19:641
36. Tagawa M (2000) Cytokine therapy for cancer. Curr Pharm Des 6:681
37. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E et al (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13:715